Riskpilot← Back to searchSign inGet full accessSANA PHARMA HOLDING AS
ASActiveOrg 916070721Philip Pedersens Vei 20, 1366 LysakerWholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2019
NOK 635K
-28% vs 2018
EBITDA margin
-1029.0%
+19% vs 2018
Equity ratio
98.9%
Financial strength
Net profit 2019
NOK -44,9M
-6% vs 2018
| Revenue | NOK 635K | -28% |
| EBITDA | NOK -6,5M | +19% |
| Net profit | NOK -44,9M | -6% |
| Total assets | NOK 631,6M | -8% |
| Equity | NOK 624,5M | -9% |
| Employees | 0 | — |
Legal name
SANA PHARMA HOLDING AS
Org number
916070721
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. oktober 2015
Share capital
NOK 20 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Være holdingselskap for investering i selskaper innenfor helse- og bioteknologiindustri, samt investeringer i andre selskaper med tilgrensende virksomhet.
Address
Philip Pedersens Vei 20, 1366 Lysaker
Phone
+4791767017
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 701 | 4 864 | 885 | 635 |
| Staff expenses | −0 | −11 144 | −12 649 | −6 655 | −5 151 |
| EBITDA | −157 | −17 708 | −11 783 | −8 088 | −6 534 |
| Depreciation & amort. | −0 | −7 | −215 | −417 | −476 |
| EBIT | −157 | −17 715 | −11 998 | −8 504 | −7 010 |
| Net financials | 20 157 | 102 328 | 834 844 | −33 749 | −37 874 |
| Profit before tax | 20 000 | 84 613 | 822 846 | −42 254 | −44 884 |
| Tax | −0 | 22 | −22 | −0 | −0 |
| Net profit | 20 000 | 84 591 | 822 868 | −42 254 | −44 884 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Total assets | 20 651 | 327 133 | 857 160 | 687 756 | 631 576 |
| Equity | 20 200 | 104 791 | 847 659 | 685 405 | 624 522 |
| Long-term debt | 0 | 80 351 | 1 612 | 0 | 0 |
| Short-term debt | 451 | 141 990 | 7 889 | 2 350 | 7 054 |
| Total debt | 451 | 222 341 | 9 501 | 2 350 | 7 054 |
EBITDA margin
-1029.0%
This company
15.8%
Market median
-6613% vs market
20152019
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20152019
Return on equity
-7.2%
This company
18.4%
Market median
-139% vs market
20152019
Net profit margin
-7068.3%
This company
8.1%
Market median
-87363% vs market
20152019
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152019
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20152019
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AK Chief Executive Officer | Chief Executive Officer | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2015 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SANA PHARMA HOLDING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andres Kongsgaard Flaaten | Chief Executive Officer | 0 companies |
| Kenneth Frode Goovaerts Bern | Chairman | 0 companies |